KRAS and familial pancreatic carcinoma: Mutations in these genes are the most commonly encountered mutations in the majority of patients with pancreatic cancer, although potential therapeutic-target genes are limited to KRAS G12C and CDKN2A, which are found only in a small subgroup of patients.